Results 51 to 60 of about 15,719 (229)

An Economic Evaluation of Direct Oral Penicillin Challenge for De‐Labelling Low Risk Patients With a Penicillin Allergy Label

Clinical &Experimental Allergy, Volume 55, Issue 5, Page 378-390, May 2025.
The cost of the Direct Oral Penicillin Challenge (DPC) itself is only a fraction of the full costs required to test for a penicillin allergy label by non‐allergists. The costs of DPC varied between hospitals using a nurse‐led, pharmacist‐led, or mixture of pharmacists and nurses.
R. Bestwick, R. Bhogal, K. Kildonaviciute, B. Y. Ng, B. Jackson, C. Moriarty, C. Thomas, L. Savic, S. A. Misbah, M. T. Krishna, R. Mujica‐Mota   +10 more
wiley   +1 more source

Inhibition of Alternative and Terminal Complement Pathway Components Modulate the Immune Response Against Bacteria and Fungi in Whole Blood

Scandinavian Journal of Immunology, Volume 101, Issue 5, May 2025.
Complement inhibition (factor D, C3, C5, or C5aR1) blunts inflammation induced by Escherichia coli or Aspergillus fumigatus conidia in lepirudin‐treated whole blood. Inhibition decreases inflammatory markers, reduces anaphylatoxin receptor expression, and lowers cytokine production and phagocytic activity. Created in https://BioRender.com.
Leon Cyranka, Ida Mariegaard, Beatrice Fageräng, Laura Pérez‐Alós, Verena Harpf, Tom Eirik Mollnes, Peter Garred, Anne Rosbjerg   +7 more
wiley   +1 more source

Mortality and morbidity in community-acquired sepsis in European pediatric intensive care units: a prospective cohort study from the European Childhood Life-threatening Infectious Disease Study (EUCLIDS)

Critical Care, 2018
Background Sepsis is one of the main reasons for non-elective admission to pediatric intensive care units (PICUs), but little is known about determinants influencing outcome.
Navin P. Boeddha, Luregn J. Schlapbach, Gertjan J. Driessen, Jethro A. Herberg, Irene Rivero-Calle, Miriam Cebey-López, Daniela S. Klobassa, Ria Philipsen, Ronald de Groot, David P. Inwald, Simon Nadel, Stéphane Paulus, Eleanor Pinnock, Fatou Secka, Suzanne T. Anderson, Rachel S. Agbeko, Christoph Berger, Colin G. Fink, Enitan D. Carrol, Werner Zenz, Michael Levin, Michiel van der Flier, Federico Martinón-Torres, Jan A. Hazelzet, Marieke Emonts, on behalf of the EUCLIDS consortium   +25 more
doaj   +1 more source

Escherichia coli in the production of biopharmaceuticals

Biotechnology and Applied Biochemistry, Volume 72, Issue 2, Page 528-541, April 2025.
Abstract Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the
İbrahim İncir, Özlem Kaplan
wiley   +1 more source

Public health management of invasive meningococcal disease outbreaks: worldwide 1973–2018, a systematic review

BMC Public Health
Background Infectious disease outbreaks are an ongoing public health concern, requiring extensive resources to prevent and manage. Invasive Meningococcal Disease (IMD) is a severe outcome of infection with Neisseria meningitidis bacteria, which can be ...
Brianna R. Morello, Adriana Milazzo, Helen Siobhan Marshall, Lynne C. Giles   +3 more
doaj   +1 more source

Genetic Variation in NFKBIE Is Associated With Increased Risk of Pneumococcal Meningitis in Children

EBioMedicine, 2016
Background: Streptococcus pneumoniae and Neisseria meningitidis are frequent pathogens in life-threatening infections. Genetic variation in the immune system may predispose to these infections.
Lene F. Lundbo, Zitta Barrella Harboe, Louise N. Clausen, Mads V. Hollegaard, Henrik T. Sørensen, David M. Hougaard, Helle B. Konradsen, Mette Nørgaard, Thomas Benfield   +8 more
doaj   +1 more source

EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non‐Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial

eJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Introduction SB12 demonstrated equivalence to reference eculizumab (ECU) in complement inhibitor‐naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) in the previous randomized, double‐blind, multi‐national, crossover, Phase III study.
Jun Ho Jang, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Jihye Park, Younsoo Kim, Jinah Jung, Paola Russo, Soo Min Lim, Régis Peffaultde Latour   +9 more
wiley   +1 more source

Invasive Meningococcal Disease, Utah, 1995–2005

Emerging Infectious Diseases, 2007
Trends in invasive meningococcal disease in Utah during 1995–2005 have differed substantially from US trends in incidence rate and serogroup and age distributions.
Rachelle B. Boulton, Stephen C. Alder, Susan Mottice, A. Peter Catinella, Carrie L. Byington   +4 more
doaj   +1 more source

Position statement on the management of pregnancy in sickle cell disease

Australian and New Zealand Journal of Obstetrics and Gynaecology, Volume 65, Issue 2, Page 183-189, April 2025.
Sickle cell disease (SCD) is a hereditary haemoglobinopathy which causes multi‐organ dysfunction. Pregnancies in SCD are high risk with significant maternal and fetal morbidity and mortality, including vaso‐occlusive crises, thrombosis, anaemia, placental insufficiency, fetal growth restriction, preterm birth and medication effects. High level evidence
Mimi Yue, Kylie Mason, Shelley Rowlands, Zane Kaplan, Debra Kennedy, Giselle Kidson‐Gerber   +5 more
wiley   +1 more source

Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination

Human Vaccines & Immunotherapeutics, 2019
Invasive meningococcal disease (IMD) caused by Neisseria meningitidis is characterized by high mortality and morbidity. While IMD incidence peaks in both infants and adolescents/young adults, carriage rates are often highest in the latter age groups ...
Cynthia Burman, Lidia Serra, Charles Nuttens, Jessica Presa, Paul Balmer, Laura York   +5 more
doaj   +1 more source